Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 17
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
16 and over
Other
MK1-192
NCT00180128
2.
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
18 and over
Other
LAP-R2007
NCT00504764
3.
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 to 60
Other
AMLSG07-04
NCT00151242
Last Modified:
4/28/2008
 
First Published:
5/21/2007
4.
Phase II/III Randomized Study of Therapy Optimization Comprising Induction, Consolidation, and Intensification Regimens Followed By CNS Radiotherapy and Maintenance Therapy Comprising Thioguanine and Cytarabine in Pediatric Patients With Standard-Risk or High-Risk Acute Myeloid Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 and under
Other
UCHM-AML-BFM-2004
UCHM-BfArM 4022064, NCT00111345, UCHM-DKH 50-2728, EU-20723, AML-BFM 2004
5.
Acute Promyelocytic Leukemia 2006 (APL)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
P050604
NCT00378365
Last Modified:
6/5/2007
 
First Published:
5/23/2007
6.
Phase III Randomized Study of Arsenic Trioxide and Tretinoin Versus Combination Chemotherapy Comprising Tretinoin, Idarubicin, Mitoxantrone Hydrochloride, Methotrexate, and Mercaptopurine for Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 70
Other
GIMEMA-DSL-APL0406
EUDRACT-2006-006188-22, APL0406, EU-20725, NCT00482833
Last Modified:
1/14/2009
 
First Published:
6/21/2007
7.
Phase III Randomized Study of Induction and Consolidation Combination Chemotherapy With or Without Gemtuzumab Ozogamicin Followed By Maintenance Therapy Comprising Tretinoin, Mercaptopurine, and Methotrexate Versus Observation in Patients With Previously Untreated Low- or Intermediate-Risk Acute Promyelocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
SWOG-S0521
S0521, NCT00492856
8.
Differentiation Induction in Acute Myelogenous Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
REK-Vestnr21503
NCT00175812
Last Modified:
10/12/2006
 
First Published:
9/23/2006
9.
Phase I/II Study of Decitabine and Tretinoin in Patients With Myelodysplastic Syndromes
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
MSKCC-06054
NCT00382200
10.
5-Azacytidine Valproic Acid and ATRA in AML and High Risk MDS
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
P050202
NCT00339196
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute